Abstract
Epidemiological studies have demonstrated an inverse correlation between plasma concentrations of highdensity lipoprotein cholesterol (HDL-C) and incidence of coronary heart disease (CHD); thus new therapies for raising HDL-C levels have been the focus of significant efforts by the cardiovascular medicine community. Inhibition of cholesteryl ester transfer protein (CETP) is one approach to increasing HDL-C concentrations. CETP is a plasma glycoprotein that mediates the transfer of cholesteryl esters from HDL to the apoB-containing lipoproteins, with a balanced transfer of triglycerides. Inhibition of CETP results in an accumulation of cholesteryl esters in HDL, thus resulting in increased HDL-C. Pharmacological inhibition of CETP in humans has been shown to result in increased levels of HDL-C, although any beneficial effect of this inhibition on CHD has yet to be established. This review article will discuss the complex role of CETP in lipid metabolism, recent developments for small-molecule inhibitors of CETP, and future prospects for CETP inhibitors in the treatment of CHD.
Keywords: Atherosclerosis, CETP inhibitor, cholesteryl ester transfer protein, coronary heart disease, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol
Current Topics in Medicinal Chemistry
Title: Cholesteryl Ester Transfer Protein (CETP) Inhibitors
Volume: 9 Issue: 5
Author(s): Julianne A. Hunt and Zhijian Lu
Affiliation:
Keywords: Atherosclerosis, CETP inhibitor, cholesteryl ester transfer protein, coronary heart disease, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol
Abstract: Epidemiological studies have demonstrated an inverse correlation between plasma concentrations of highdensity lipoprotein cholesterol (HDL-C) and incidence of coronary heart disease (CHD); thus new therapies for raising HDL-C levels have been the focus of significant efforts by the cardiovascular medicine community. Inhibition of cholesteryl ester transfer protein (CETP) is one approach to increasing HDL-C concentrations. CETP is a plasma glycoprotein that mediates the transfer of cholesteryl esters from HDL to the apoB-containing lipoproteins, with a balanced transfer of triglycerides. Inhibition of CETP results in an accumulation of cholesteryl esters in HDL, thus resulting in increased HDL-C. Pharmacological inhibition of CETP in humans has been shown to result in increased levels of HDL-C, although any beneficial effect of this inhibition on CHD has yet to be established. This review article will discuss the complex role of CETP in lipid metabolism, recent developments for small-molecule inhibitors of CETP, and future prospects for CETP inhibitors in the treatment of CHD.
Export Options
About this article
Cite this article as:
Hunt A. Julianne and Lu Zhijian, Cholesteryl Ester Transfer Protein (CETP) Inhibitors, Current Topics in Medicinal Chemistry 2009; 9 (5) . https://dx.doi.org/10.2174/156802609788340823
DOI https://dx.doi.org/10.2174/156802609788340823 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Exploring Pharmacological Significance of Chalcone Scaffold: A Review
Current Medicinal Chemistry Prostacyclin Analogues: Prevention of Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Nitric Oxide Synthase Function in Exercise
Current Enzyme Inhibition Life-Threatening Respiratory Syncytial Virus Disease in Children
Current Respiratory Medicine Reviews Dynamic Role of Microparticles in Type 2 Diabetes Mellitus
Current Diabetes Reviews Preface: MicroRNA as Disease Biomarkers
MicroRNA Vitamin D Intake and Obesity in Occupational Asthma Patients and the Need for Supplementation
Endocrine, Metabolic & Immune Disorders - Drug Targets A Case-Control Study Investigating the Effect of MTHFR C677T Variant on Performance of Elite Athletes
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Anti-platelet Agents for the Treatment of Stable Angina Pectoris
Current Pharmaceutical Design High-density Lipoprotein, Vascular Risk, Cancer and Infection: A Case of Quantity and Quality?
Current Medicinal Chemistry Omega-3 Polyunsaturated Fatty Acids: Their Potential Role in Blood Pressure Prevention and Management
Current Vascular Pharmacology Beyond Lipoprotein Receptors: Learning from Receptor Knockouts Mouse Models about New Targets for Reduction of the Atherosclerotic Plaque.
Current Molecular Medicine COPD Management: Look Beyond the Airway Obstruction, Chronic Bronchitis and Emphysema
Current Respiratory Medicine Reviews A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
Current Cardiology Reviews Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis
Cardiovascular & Hematological Disorders-Drug Targets Effect of Doxycycline on Atherosclerosis: From Bench to Bedside
Recent Patents on Cardiovascular Drug Discovery The Lung Disease of Rheumatoid Arthritis
Current Respiratory Medicine Reviews Cytotoxic and Radio-sensitizing Effects of Polyphenolic Acetates in a Human Glioma Cell Line (BMG-1)
Current Pharmaceutical Design The Role of Anti-Inflammatory Drugs in Respiratory Diseases - Pirfenidone, Penicillamine, Chloroquine and Chlorambucil
Current Respiratory Medicine Reviews Beta Blockers and Chronic Obstructive Pulmonary Disease (COPD): Sum of Evidence
Current Hypertension Reviews